Triple GIP/GLP-1/Glucagon Receptor Agonist1 mgInvestigational

1 mg Retatrutide Dosage Calculator

Calculate the exact units for the 1 mg retatrutide initiation dose across available vial concentrations.

Retatrutide is an investigational medication currently in clinical trials. It has not been approved by the FDA for any indication.

050100

How many units is 1 mg of Retatrutide at 2 mg/mL?

Draw

50units

0.50 mL on a U-100 insulin syringe

1 mg ÷ 2 mg/mL × 100 = 50 units

For educational purposes only. Always follow your provider's instructions.

Quick Reference Table

All dose × concentration combinations

Dose2 mg/mL5 mg/mL10 mg/mL
1 mg502010
2 mg100*4020
4 mg200*80*40
8 mg400*160*80*
12 mg600*240*120*

Values in U-100 insulin syringe units

* Exceeds 50 units (0.5 mL) — may require splitting into two injections

There's an easier way

Tired of calculating doses?

We handle everything — the prescription, the right dose, and shipping straight to your door. No math, no hassle.

Get Started

2-min quiz · Free consultation · No commitment

About the 1 mg Dose

The 1 mg dose is the initiation dose for retatrutide used during weeks 1 through 4 in Phase 2 clinical trials. Retatrutide is an investigational triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. This starting dose introduces the novel mechanism gently to allow patients to acclimate before dose escalation begins.

Frequently Asked Questions

In a 5 mg/mL vial, 1 mg retatrutide equals 20 units. The calculation is (1 / 5) x 100 = 20 units. In a 2 mg/mL vial, it would be 50 units, and in a 10 mg/mL vial, it would be 10 units.

Based on Phase 2 clinical trial protocols, the retatrutide schedule starts at 1 mg (weeks 1-4), then escalates to 2 mg (weeks 5-8), 4 mg (weeks 9-12), 8 mg (weeks 13-16), and up to 12 mg (weeks 17 onward). Note that retatrutide is still investigational and the final approved schedule may differ.

No, retatrutide is not yet FDA-approved. It is currently in Phase 3 clinical trials conducted by Eli Lilly. Early trial results have been promising, showing up to 24.2% body weight loss at the 12 mg dose over 48 weeks.

Retatrutide's 1 mg starting dose introduces a unique triple-agonist mechanism that targets GIP, GLP-1, and glucagon receptors, compared to semaglutide's single GLP-1 target (starting at 0.25 mg) and tirzepatide's dual GIP and GLP-1 activity (starting at 2.5 mg). The different starting doses reflect each medication's distinct potency and receptor-binding profile.

Other Retatrutide Doses

2 mg Retatrutide4 mg Retatrutide8 mg Retatrutide12 mg Retatrutide

Related Pages

Retatrutide CalculatorRetatrutide Dosing

Ready to Get Started?

Take our 2-minute quiz to see if you qualify for GLP-1 treatment.

Start Quiz

Free consultation. No commitment.